Back to top
more

HealthEquity (HQY)

(Real Time Quote from BATS)

$91.05 USD

91.05
631,983

+0.04 (0.04%)

Updated Aug 6, 2025 02:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (73 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

MD vs. HQY: Which Stock Is the Better Value Option?

by Zacks Equity Research

MD vs. HQY: Which Stock Is the Better Value Option?

Zacks Equity Research

HealthEquity Stock Tumbles Despite the Launch of Assist Benefits Suite

by Zacks Equity Research

HQY launches Assist Suite to integrate personalized support, simplify benefits, and enhance engagement, aiming to reduce costs and improve outcomes.

Zacks Equity Research

Company News for Mar 20, 2025

by Zacks Equity Research

Companies In The Article Are:TSLA, GIS, GILD, HQY

Zacks Equity Research

HQY Stock Falls as Q4 Earnings Miss Estimates, Revenues Up Y/Y

by Zacks Equity Research

HealthEquity surpasses fourth-quarter revenue expectations on robust HSA growth. It also provided fiscal 2026 guidance.

Zacks Equity Research

HealthEquity (HQY) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for HealthEquity (HQY) give insight into how the company performed in the quarter ended January 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

HealthEquity (HQY) Q4 Earnings Miss Estimates

by Zacks Equity Research

HealthEquity (HQY) delivered earnings and revenue surprises of -2.82% and 2.20%, respectively, for the quarter ended January 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MD vs. HQY: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

MD vs. HQY: Which Stock Is the Better Value Option?

Zacks Equity Research

Gear Up for HealthEquity (HQY) Q4 Earnings: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Evaluate the expected performance of HealthEquity (HQY) for the quarter ended January 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks Equity Research

Here's Why You Should Retain HealthEquity Stock in Your Portfolio Now

by Zacks Equity Research

HQY's sustained strength in HSAs raises optimism about the stock.

Zacks Equity Research

LifeMD, Inc. (LFMD) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

LifeMD (LFMD) delivered earnings and revenue surprises of 66.67% and 12.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Natera (NTRA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Natera (NTRA) delivered earnings and revenue surprises of 2.38% and 0.88%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MD or HQY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

MD vs. HQY: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why HealthEquity (HQY) is a Strong Growth Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Agilon Health (AGL) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Agilon (AGL) delivered earnings and revenue surprises of -13.64% and 0.35%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Danaher Rewards Shareholders With 18.5% Dividend Increase

by Zacks Equity Research

DHR's measures to consistently reward shareholders through dividends and share buybacks hold promise.

Zacks Equity Research

Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Why HealthEquity (HQY) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Here's Why You Should Retain HealthEquity Stock in Your Portfolio Now

by Zacks Equity Research

HQY's sustained strength in HSAs raises optimism about the stock.

Zacks Equity Research

Why Is HealthEquity (HQY) Up 3.5% Since Last Earnings Report?

by Zacks Equity Research

HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

HealthEquity Gains 46.8% in a Year: What's Driving the Stock?

by Zacks Equity Research

HQY's sustained strength in HSAs raises optimism about the stock.

Zacks Equity Research

PACS or HQY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PACS vs. HQY: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why HealthEquity (HQY) is a Strong Growth Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

HealthEquity Stock Falls Despite Q3 Earnings and Revenue Beat

by Zacks Equity Research

HQY's fiscal third-quarter results benefit from robust HSA growth and improved gross margin. It also raises fiscal 2025 guidance.